EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Tau depletion diminishes vascular amyloid‐related deficits in a mouse model of cerebral amyloid angiopathy

Nur Jury-Garfe iD, Enrique Chimal-Juárez iD, Henika Patel iD, Jonathan Martinez-Pinto iD, Kathryn Vanderbosch, Muriel D Mardones iD, Abigail Perkins, Gonzalo Viana Di Prisco iD, Yamil Marambio, Ruben Vidal iD, Brady K Atwood iD, Cristian A Lasagna-Reeves iD

Alzheimer's & Dementia · 2025

DOI: 10.1002/alz.70238 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2025. Verfasst von Nur Jury-Garfe und 11 weiteren Autor:innen. Beteiligte Einrichtung: Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Cerebral Amyloid Angiopathy, tau Proteins. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIA NIH HHS, NCATS NIH HHS, Alzheimer's Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION Tau is essential for amyloid beta (Aβ)–induced synaptic and cognitive deficits in Alzheimer's disease (AD), making its downregulation a therapeutic target. Cerebral amyloid angiopathy (CAA), a major vascular contributor to cognitive decline, affects over 90% of patients with AD. This study explores the impact of tau downregulation on CAA pathogenesis. METHODS We crossed the Familial Danish Dementia mouse model (Tg‐FDD), which develops vascular amyloid, with tau‐null (mTau −/− ) mice to generate a CAA model lacking endogenous tau (Tg‐FDD/mTau −/− ). Behavioral, electrophysiological, histological, and transcriptomic analyses were performed. RESULTS Tau depletion ameliorated motor and synaptic impairments, reduced vascular amyloid deposition, and prevented vascular damage. Tau ablation also mitigated astrocytic reactivity and neuroinflammation associated with vascular amyloid accumulation. CONCLUSION These findings provide the first in vivo evidence of the beneficial effects of tau downregulation in a CAA mouse model, supporting tau reduction as a potential therapeutic strategy for patients with parenchymal and vascular amyloid deposition. Highlights Tau ablation improves motor function and synaptic impair, reduces cerebrovascular amyloid deposits, and prevents vascular damage in a mouse model of cerebral amyloid angiopathy (CAA). Tau reduction decreases astrocytic reactivity, alters neuroinflammatory gene expression, and enhances oligodendrocyte function, suggesting a protective role against neuroinflammation in CAA. These findings highlight tau reduction as a potential therapeutic strategy to mitigate CAA‐induced pathogenesis, with implications for treating patients with both parenchymal and vascular amyloid deposition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cerebral Amyloid Angiopathytau ProteinsAnimalsDisease Models, AnimalMiceMice, TransgenicAmyloid beta-PeptidesBrainMice, Knockout

Stichwörter der Autor:innen

cerebral amyloid angiopathyneuroinflammationtauvascular amyloid

Substanzen

tau ProteinsAmyloid beta-Peptides

Autor:innen und Institutionen

  • Stark Neurosciences Research Institute, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Department of Anatomy, Cell Biology, and Physiology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Department of Neurology, Baylor College of Medicine, Houston, Texas, USA.
  • Facultad de Ciencias, Instituto de Fisiología, Universidad de Valparaíso, Valparaíso, Chile.
  • Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.

ORCID-Profile: Nur Jury-Garfe, Enrique Chimal-Juárez, Henika Patel, Jonathan Martinez-Pinto, Muriel D Mardones, Gonzalo Viana Di Prisco, Ruben Vidal, Brady K Atwood, Cristian A Lasagna-Reeves

Förderung

  • NIA NIH HHS
  • NCATS NIH HHS
  • Alzheimer's Association
  • NIH/NIA
  • Indiana Clinical and Translational Sciences Institute
  • Cure Alzheimer's Fund
  • NINDS NIH HHS
  • NIH/NINDS

Zitieren

APA

Jury-Garfe, N., Chimal-Juárez, E., Patel, H., Martinez-Pinto, J., Vanderbosch, K., Mardones, M. D., Perkins, A., Prisco, G. V. D., Marambio, Y., Vidal, R., Atwood, B. K., & Lasagna-Reeves, C. A. (2025). Tau depletion diminishes vascular amyloid‐related deficits in a mouse model of cerebral amyloid angiopathy. Alzheimer's & Dementia. https://doi.org/10.1002/alz.70238

Vancouver

Jury-Garfe N, Chimal-Juárez E, Patel H, Martinez-Pinto J, Vanderbosch K, Mardones MD, et al. Tau depletion diminishes vascular amyloid‐related deficits in a mouse model of cerebral amyloid angiopathy. Alzheimer's & Dementia. 2025. doi:10.1002/alz.70238

BibTeX
@article{JuryGarfe2025,
  author = {Jury-Garfe, Nur and Chimal-Juárez, Enrique and Patel, Henika and Martinez-Pinto, Jonathan and Vanderbosch, Kathryn and Mardones, Muriel D and Perkins, Abigail and Prisco, Gonzalo Viana Di and Marambio, Yamil and Vidal, Ruben and Atwood, Brady K and Lasagna-Reeves, Cristian A},
  title = {Tau depletion diminishes vascular amyloid‐related deficits in a mouse model of cerebral amyloid angiopathy},
  journal = {Alzheimer's & Dementia},
  year = {2025},
  doi = {10.1002/alz.70238}
}
Kostenlos starten →